Davis A, Brogan AJ, Talbird S, Wild L, Flanagan D. The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018 Nov;17(11):1021-35. doi: 10.1080/14760584.2018.1538801
Talbird SE, La EM, Maurer N, Vidal J, Rangel Miller V. Is the CADASIL Family Registry research ready? Poster presented at the 2018 National Organization for Rare Disorder (NORD) Rare Diseases & Orphan; October 15, 2018. Washington, DC.
La EM, Talbird SE, Kanadanian KV, Fain J, Huang L, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Poster presented at the 2018 IDWeek Conference; October 4, 2018. San Francisco, CA.
Talbird SE, La EM, Carrico J, Poston S, Poirrier J, DeMartino JK, Hogea C. Projected burden of vaccine-preventable diseases in older adults in the United States: impact of population aging. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Supplement 3):S225.
La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom. Eur J Cancer Care (Engl). 2018 Sep;27(5):e12862. doi: 10.1111/ecc.12862
Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.
Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.
Talbird SE, Hogea CS, Meyers J, Carrico J, Buck PO. Cost-effectiveness of a 10-year revaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (TDaP) vaccine among individuals with pre-existing asthma in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S153. doi: 10.1016/j.jval.2018.04.1062
Brennan VK, Talbird SE, Beard SM, Brogan AJ, Flanagan D, Delpech V, Bosanquet N, Fisher M. The public health and economic impact from earlier diagnosis and earlier antiretroviral treatment of HIV in the UK. Poster presented at the 14th European AIDS Conference/EACS; October 16, 2013.
Odom DM, Talbird SE, Brogan AJ, Schenkel B. A meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the Summer Meeting of the American Academy of Dermatology; August 2013.
Brogan A, Talbird S, Thompson J, Kim Y, Olson J, Peterson J, Piontkowsky D, Pietrandoni G. Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single-tablet antiretroviral regimen for HIV treatment, to US third-party payers. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2, 2013. Dublin, Ireland. [abstract] Value Health. 2013 Aug; 16(7):A343-4.
Odom D, Brogan AJ, Talbird SE, Schenkel B. A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. [abstract] Value Health. 2013 May; 16(3):A112. doi: 10.1016/j.jval.2013.03.532
Myers RP, Brogan AJ, Talbird SE, Thompson J, Marcellin P, Jacobson IM, DeMasi R, Menzie AM, Yoshida EM. Efficacy, safety, and cost-effectiveness in Canada of telaprevir combination therapy by baseline fibrosis stage in treatment-naïve patients with chronic genotype 1 hepatitis C virus infection. Presented at the 2013 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; March 2013.